Impact of an emergency department pharmacy on medication omission and delay

Greg P Marconi1, Ilene Claudius

  • 1Department of Pediatrics, Division of Emergency and Transport Medicine, Children's Hospital of Los Angeles, Los Angeles, CA 90027, USA. gmarconi@chla.usc.edu

Pediatric Emergency Care
|December 24, 2011
PubMed

Insights

Adding a clinical pharmacist to a pediatric emergency department (ED) significantly reduced medication omissions and delays, especially for patients with prolonged stays. This improvement in medication safety was sustained over time.

Area of Science:

  • Pharmacology
  • Emergency Medicine
  • Patient Safety

Background:

  • Medication omissions and delays are frequent in emergency departments (EDs).
  • Patients with prolonged ED stays (≥8 hours) face heightened risks of medication errors.
  • The role of clinical pharmacists in optimizing medication management within ED settings requires further investigation.

Purpose of the Study:

  • To assess the impact of integrating a clinical pharmacist into a pediatric ED.
  • To evaluate changes in medication omissions and delays for patients with extended ED stays (≥8 hours).
  • To determine the effect on medication errors in this specific patient population.

Main Methods:

  • Retrospective review of medication omissions and delays.
  • Data collected from a tertiary-care children's hospital ED.
  • Analysis conducted during three periods: pre-pharmacist, immediately post-pharmacist, and 6 months post-pharmacist addition.

Main Results:

  • Significant reductions in both urgent and nonurgent medication omissions/delays were observed immediately after pharmacist integration (P < 0.0001).
  • These improvements were sustained at 6 months, with nonurgent medications showing statistical significance (P < 0.0001).
  • For patients with prolonged ED stays (≥8 hours), medication omission/delay rates dropped from 52.8% to 28.6% immediately after pharmacist addition.

Conclusions:

  • Emergency departments experience high rates of medication omissions and delays.
  • Prolonged ED boarding increases the risk of medication administration errors.
  • Integrating clinical pharmacists into EDs can effectively decrease medication omissions and delays, enhancing patient safety.
Abstract

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...